These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 8414460)

  • 1. [Smoldering myeloma].
    Dolgos J; Patakfalvi A
    Orv Hetil; 1993 Sep; 134(39):2155-7. PubMed ID: 8414460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
    Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
    Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: recognition and management.
    George ED; Sadovsky R
    Am Fam Physician; 1999 Apr; 59(7):1885-94. PubMed ID: 10208707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
    Gruber A; Osby E
    Chemioterapia; 1987 Jun; 6(2 Suppl):725-6. PubMed ID: 3509531
    [No Abstract]   [Full Text] [Related]  

  • 5. IgD multiple myeloma. A report of three cases.
    Martini R; Santini S; Bottari G
    Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
    Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
    Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
    Franchi F; Seminara P; Rossi Fanelli F
    Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nonproducing myeloma without evident bone lesion].
    Kawatani T; Maeda N; Hosoda A; Agou H; Nakai K; Kawasaki H
    Rinsho Ketsueki; 1990 Jun; 31(6):842-6. PubMed ID: 2214175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [IgD myeloma. Presentation of a case and review of the literature].
    Fiore G; Baraldi A; Cremonte LG; Marenco M
    Minerva Med; 1990; 81(1-2):103-5. PubMed ID: 2314611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma: diagnosis and treatment.
    Nau KC; Lewis WD
    Am Fam Physician; 2008 Oct; 78(7):853-9. PubMed ID: 18841734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rapid growth of glioblastoma during therapy for multiple myeloma: case report].
    Sonoda Y; Kumabe T; Umezawa K; Shimizu H; Murakawa Y; Kanamaru R; Yoshimoto T
    No Shinkei Geka; 1998 Aug; 26(8):737-41. PubMed ID: 9744004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma.
    Hayes MJ; Carey JL; Krauss JC; Hedstrom DL; Gulbranson RL; Keren DF
    Eur J Haematol; 2007 Apr; 78(4):353-7. PubMed ID: 17378894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment.
    Carlson K; Aström G; Nyman R; Ahlström H; Simonsson B
    Acta Radiol; 1995 Jan; 36(1):9-14. PubMed ID: 7833177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcome in solitary bone plasmacytomata with combined therapy.
    Avilés A; Huerta-Guzmán J; Delgado S; Fernández A; Díaz-Maqueo JC
    Hematol Oncol; 1996 Sep; 14(3):111-7. PubMed ID: 9119355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
    Hájek R; Adam Z; Vásová I; Král Z
    Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.